Navigation Links
Research-Based Biopharmaceutical Company Awards Trials to DATATRAK
Date:8/25/2009

CLEVELAND, Aug. 25 /PRNewswire-FirstCall/ -- DATATRAK International, Inc.(OTCQX: DATA), a technology and services company focused on global eClinical solutions for the clinical trials industry, today announced the signing of two new studies with a global research-based biopharmaceutical company. The award includes a multi-site, five-year study and demonstrates a long-term commitment to the DATATRAK eClinical(TM) platform.

"We are pleased that our partnership with this biopharmaceutical continues to grow," said Laurence Birch, DATATRAK's Chairman of the Board. "The signing of new business with existing clients validates our technology and service delivery model, DATATRAK ONE(TM). Our Enterprise Transfer clients are able to successfully develop and deliver trials utilizing DATATRAK's technology and online resources."

DATATRAK eClinical(TM) empowers clinical users and service providers with the tools necessary for efficiently conducting, delivering and managing clinical trials. Built upon a unified architecture, eClinical's Clinical Suite, Trial Manager, Enterprise Manager and Enterprise Platform components provide the foundation for end-to-end Clinical Trial Solutions. Whether deploying products via DATATRAK's Enterprise Transfer program or relying on the DATATRAK team for project delivery as a Software as a Service (SaaS) client, DATATRAK provides the most complete product and service offering for the Clinical Trial Life Cycle.

About DATATRAK International, Inc.

DATATRAK International, Inc. is a worldwide technology company focused on the provision of multi-component eClinical solutions and related services for the clinical trials industry. We operate under the concept of DATATRAK ONE(TM), which encompasses our unique, single platform technology. The singular architecture of our DATATRAK eClinical(TM) product suite has been embraced by clients around the globe for its ability to effectively manage clinical trials through an integrated multi-component, comprehensive solution. The Company delivers a complete portfolio of software products that were created in order to accelerate clinical research data from investigative sites to clinical trial sponsors and ultimately the FDA, faster and more efficiently than manual methods or loosely integrated technologies. DATATRAK's eClinical((TM)) software suite can be deployed worldwide through an ASP offering or in a licensed Enterprise Transfer model that fully empowers its clients. The DATATRAK software suite and its earlier versions have successfully supported hundreds of international clinical trials involving thousands of clinical research sites and encompassing tens of thousands of patients in 59 countries. DATATRAK International, Inc.'s product suite has been utilized in some aspect of the clinical development of 16 drugs and one medical device that have received regulatory approval from either the United States Food and Drug Administration or counterpart European bodies. DATATRAK International, Inc. has offices located in Cleveland, Ohio, and Bryan, Texas. Visit the DATATRAK International, Inc. web site at www.datatrak.net.

Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. These forward-looking statements are made based on management's expectations, assumptions, estimates and current beliefs concerning the operations, future results and prospects of the Company and are subject to uncertainties and factors (including those specified below) which are difficult to predict and, in many instances, are beyond the control of the Company. Factors that may cause actual results to differ materially from those in the forward-looking statements include the limited operating history on which the Company's performance can be evaluated; the ability of the Company to continue to enhance its software products to meet customer and market needs; fluctuations in the Company's quarterly results; the viability of the Company's business strategy and its early stage of development; the timing of clinical trial sponsor decisions to conduct new clinical trials or cancel or delay ongoing trials; the Company's dependence on major customers; government regulation associated with clinical trials and the approval of new drugs; the ability of the Company to compete in the emerging EDC market; losses that potentially could be incurred from breaches of contracts or loss of customer data; the inability to protect intellectual property rights or the infringement upon other's intellectual property rights; the costs associated with maintaining and/or developing two product suites; and general economic conditions such as the rate of employment, inflation, interest rates and the condition of capital markets. This list of factors is not all-inclusive. In addition, the Company's success depends on the outcome of various strategic initiatives it has undertaken, all of which are based on assumptions made by the Company concerning trends in the clinical research market and the health care industry. The Company undertakes no obligation to update publicly or revise any forward-looking statement whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE DATATRAK International, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Eiger BioPharmaceuticals Announces Initiation of CLEAN-1 HCV Phase 1b Trial
2. Keryx Biopharmaceuticals, Inc. Commences Phase 1 Study of KRX-0401 (Perifosine) in Recurrent Pediatric Solid Tumors at Memorial Sloan-Kettering Cancer Center
3. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
4. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
5. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
6. Plasma Products Safe Despite Swine Influenza Outbreak, Assures International Biopharmaceutical Company Octapharma
7. XTL Biopharmaceuticals Announces the Acquisition of the Use Patent on Recombinant Erythropoietin (rHuEPO) for the Treatment of Multiple Myeloma
8. R&D Spending by U.S. Biopharmaceutical Companies Reaches Record Levels in 2008 Despite Economic Challenges
9. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
10. Inspiration Biopharmaceuticals, Inc. Initiates Phase 1 Clinical Trial of IB1001 for the Treatment of Hemophilia B
11. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... -- 7D Surgical announced today that it has ... and Drug Administration (FDA) and a medical device ... commercial launch of its innovative Machine-vision Image Guided ... Surgical System.  The 7D Surgical ... vision algorithms to eliminate the long-standing barriers to ...
(Date:1/23/2017)... WASHINGTON , Jan. 23, 2017 The ... of the Pharmacy and Medically Underserved Areas ... House of Representatives. The legislation, which was previously introduced ... improve patient access to health care through pharmacists and ... bill include Representatives Brett Guthrie (R-KY), ...
(Date:1/23/2017)... 23, 2017 Stock-Callers.com today presents the ... CPRX ), Sophiris Bio Inc. (NASDAQ: ... and Agile Therapeutics Inc. (NASDAQ: AGRX ). These ... lower in late trade on Friday, January 20 th , ... while shares of health care companies in the S&P 500 ...
Breaking Medicine Technology:
(Date:1/23/2017)... TAMPA, Fla. (PRWEB) , ... January 23, 2017 ... ... for the nonprofit educational institution’s inaugural K-20 Education Summit to be held March ... proposals to present by Jan. 25, 2017. , The keynote speakers include Dr. ...
(Date:1/23/2017)... ... 23, 2017 , ... The iaedp Foundation, recognized for its ... who treat the full spectrum of eating disorder problems, proudly announces the addition ... of the leading eating disorder treatments centers located throughout the U.S. As partners ...
(Date:1/23/2017)... Dc (PRWEB) , ... January 23, 2017 , ... ... American University is taught by healthcare management and evaluation leaders with decades of ... fee-for-service to pay-for-value in the United States healthcare system, there is a renewed ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... in North America for the scientific development, healthcare training and clinical application of ... and its 2017 AAT Member Certification Qualification Courses for Technicians, respectively. , For ...
(Date:1/23/2017)... ... January 23, 2017 , ... METTLER TOLEDO ... Process Chemistry by Applying Simple PAT Tools . , Crystallization is ... purify the desired product. Chemists now spend more time developing better intermediate ...
Breaking Medicine News(10 mins):